Individualized Antisense Oligonucleotide Therapy for SCN2A-Related Epilepsy Researchers have successfully designed and administered patient-specific antisense oligonucleotides (ASOs) to treat two individuals with intractable epilepsy caused by pathogenic variants in the …
Tag: